Search

everythinglearnresearchcommunity

for

Search:↓

An imbalance between certain immune cells is linked to a chronic skin condition and may be influenced by obesity, smoking, and autoimmune issues.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

Autoimmune hair loss may be linked to increased Th1 and Th17 cells and decreased Th2 cells.

Finasteride reduces some inflammation in BPH but not all.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

IL-26 has antimicrobial and pro-inflammatory effects in the chronic skin condition Hidradenitis Suppurativa.

Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.

A vitamin D receptor mutation causes rickets and affects immune responses.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Selective Androgen Receptor Modulators (SARMs) are drugs that can control the effects of androgens in different tissues, potentially having fewer side effects and promising for treating various conditions.

T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.

Blocking IL-17 signaling can delay skin aging and improve skin and hair health.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Atopic dermatitis may trigger alopecia areata, and early treatment can help prevent severe cases.

Janus kinase inhibitors show promise for treating alopecia areata in children.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.

Blocking IL-17a can improve age-related smell loss in mice.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.

Different immune responses cause hair loss in scalp diseases, with unique patterns in scalp psoriasis possibly protecting against hair loss.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.